In an MLL-AF9-driven mouse model of AML, knockdown on Mtss1 drastically shortened time to disease onset, increased leukemic burden, and augmented ex vivo chemotherapy resistance. The gene discussed is MTSS1; the disease is acute myeloid leukemia.